The Latest Cardiac and Vascular News
Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with thestrong CYP2D6 inhibitor, paroxetine SAN DIEGO, May 17, 2022 /PRNewswire/ — HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the successful completion of a Phase 1 drug-drug interaction clinical trial of HBI-3000, a novel drug for cardioversion […]
Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation SAN DIEGO, Feb. 28, 2020 /PRNewswire/ — HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, has presented the results of a Phase I study of HBI-3000, a novel drug for cardioversion of atrial fibrillation (AF). […]
